M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Products of the Russian Academy of Sciences submitted to the Russian Ministry of Health an application for clinical trials of the first Russian inactivated polio vaccine (IPV).
The Russian drug was developed in accordance with the latest requirements of the World Health Organization and is based on attenuated Sabin strains, while the vaccines currently available on the international market are formulated based on the wild strains of poliovirus. The original strain used in the Russian vaccine is owned by M. P. Chumakov Center, which provides the full cycle of manufacturing the drug.
The registration of Russian IPV is expected to be completed by the end of 2018. M.P. Chumakov Center also plans to create a combination vaccine with IPV component, that will significantly reduce the injection burden on children.
“Inactivated polio vaccine is a unique innovative drug which, at this point, has no analogs on the global market. All stages of its development, being a long and laborious process, have been carried out by Russian specialists. Taking into account the global shortage of IPVs and the complicated international situation, the availability of domestically produced innovative vaccine guarantees the epidemiological security of Russia,” said Aydar Ishmukhametov, the General Director of M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Products of the Russian Academy of Sciences.